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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYDespite over a decade of intense research, the identity and differentiation potential of human adult cardiac progenitor cells (aCPC)
remains controversial. Cardiospheres have been proposed as a means to expand aCPCs in vitro, but the identity of the progenitor cell
within these 3D structures is unknown. We show that clones derived from cardiospheres could be subdivided based on expression of
thymocyte differentiation antigen 1 (THY-1/CD90) into two distinct populations that exhibit divergent cardiac differentiation potential.
One population, which is CD90+, expressed markers consistent with a mesenchymal/myofibroblast cell. The second clone type was
CD90 and could form mature, functional myocytes with sarcomeres albeit at a very low rate. These two populations of cardiogenic
clones displayed distinct cell surface markers and unique transcriptomes. Our study suggests that a rare aCPC exists in cardiospheres
along with a mesenchymal/myofibroblast cell, which demonstrates incomplete cardiac myocyte differentiation.INTRODUCTION
Adult cardiac progenitor cells (aCPCs) are a rare subpopula-
tion of cells first reported in the adult rat heart that are self-
renewing, clonogenic, and multipotent with the capacity
to give rise to cardiac myocytes (CMs), smoothmuscle cells
(SMCs), and endothelial cells (ECs) in vitro and in vivo
(Beltrami et al., 2003). Their biology, particularly human
aCPCs, remains poorly understood because techniques to
study human aCPCs in vivo are very limited, and in vitro
studies are challenging due to the rarity of this cell type
and lack of reliablemethods to propagate and expand these
cells in their undifferentiated state. Cardiosphere (CS) for-
mation, a 3D culture system, has been proposed as one
method to expand aCPCs in vitro (Messina et al., 2004;
Davis et al., 2009). Sphere systems have been used to
culture many stem cell types, including neural and skin
stem cells (Reynolds and Weiss, 1992; Fernandes et al.,
2004; Gago et al., 2009). Rat CS-derived clones aremultipo-
tent (Davis et al., 2009), but whether these cells exist in
humanCS or their identity is unknown. CSs are a heteroge-
neous mix of nonmyocyte cells derived from the mononu-
clear fraction of dissociated heart tissue, which includes
mesenchymal stem cells, SMCs, ECs, and cardiac fibro-
blasts. Although CSs have been reported to contain an
aCPC, this has been questioned, and its identity or cell
surface markers that can be used to isolate these cells are
unknown (Masuda et al., 2012; Smith et al., 2007). Interest-
ingly, there is no panel of cell surface markers that can
directly identify endogenous CPCs. Numerous putative576 Stem Cell Reports j Vol. 2 j 576–591 j May 6, 2014 j ª2014 The AuthorsaCPCs have been reported in adult mouse heart, which
were identified based on the expression of C-KIT, SCA1,
or the ability to exclude Hoechst dye (Beltrami et al.,
2003; Oh et al., 2004; Tomita et al., 2005). Much less data
exist in human hearts, although a rare cardiac progenitor
cell population of C-KIT and NKX2.5+ cells has been
described (Mishra et al., 2011; Goumans et al., 2007; Bearzi
et al., 2007; Smits et al., 2009). However, C-KIT by itself is
not specific and cannot be used by itself to identify aCPCs
(Bearzi et al., 2009; Sandstedt et al., 2010). A significant pro-
portion of the C-KIT cells in human hearts coexpresses
CD45, suggesting that theymay be hematopoietic in origin
(Kubo et al., 2008). The early cardiac transcription factor,
NK2 homeobox 5 (NKX2.5), is often used in conjunction
with c-KIT to identify aCPCs (Wu et al., 2006, 2008; Mishra
et al., 2011), but because it is an intracellular marker, its use
is restricted to fixed cells and cannot be used for purifying
human live cells. At least a subset of cardiac C-KIT cells
expressed NKX2.5, but whether this C-KIT+/NKX2.5+ sub-
population in adult human heart is an authentic aCPC
and whether this C-KIT+/NKX2.5+ cell also represents the
aCPCs within CS is unknown. No systematic analysis of
cell surface markers of cloned human aCPCs has been per-
formed, and nopanel of cell surfacemarkers allowing direct
isolation of aCPCs is available.
Another major limitation of the adult cardiac stem cell
field is the inability to get full differentiation from putative
stem/progenitor cells in vitro or in vivo. In fact, although
expression of cardiac genes and proteins is demonstrated
frequently, the levels, relative to authentic CMs, and their
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are rarely quantified (Barile et al., 2007; Bearzi et al.,
2007; He et al., 2011). In vivo engraftment studies have
often demonstrated low-level retention of cells that,
whereas expressing sarcomeric proteins, do not morpho-
logically appear to resemble adult CMs (Li et al., 2010).
This is also true of the CMs differentiated from human
CS (Davis et al., 2009). The basis for this paradox is un-
known but is a critical issue to resolve if these cells are
to be used therapeutically. Despite these limitations, the
therapeutic efficacy of autologous CS-derived cells after
myocardial infarction was tested in a recent clinical trial
byMakkar et al. (2012). The authors reported that the ther-
apy appeared safe, reduced myocardial scar, and increased
viable myocardium, but there was no global improvement
in patients’ cardiac function.
In the present study, we sought to determine the identity
of the cell(s) with cardiogenic potential in CS generated
from human hearts. We describe two distinct populations
of CS-derived cells based on their expression of CD90 and
their cardiomyogenic potential. The first cell population
is enriched for the cardiac transcription factor NKX2.5
and ISL1 but negative formesenchymal stem cell/fibroblast
surface marker CD90 and negative for cardiac stem cell
marker C-KIT. These CD90 cells can differentiate into
SMCs, ECs, and CMs, which form complete sarcomeres
and beat spontaneously but at a very low frequency.
The second cell population appears to be a cardiac
mesenchymal/fibroblast cell that is positive for CD90 and
Periostin but is NKX2.5low and ISL1low. This cell demon-
strated endothelial and SMC differentiation but only
incomplete cardiac differentiation into CM-like cells
without sarcomere formation or calcium cycling. These re-
sults may account for previous reports of multiple stem
cells in the heart (Barile et al., 2007; Beltrami et al., 2003;
Davis et al., 2010; Deb et al., 2003; Laflamme et al., 2002;
Murry et al., 2004; Toma et al., 2002) and suggest that a
cell with a phenotype consistent with a mesenchymal
stem cell or myofibroblast exists in the adult heart that is
capable of differentiating into CM-like cells that are not
authentic mature CMs.RESULTS
Differentiation of Adult Human CS-Derived Cells
Primarily Gives Rise to Immature CM-like Cells
Heart-derived cells (HDCs) obtained from first plating of
acutely dissociated mononuclear human cells were plated
in adherent culture (ADH) or used to create CSs (Figure 1A).
Undifferentiated HDCs, ADHs, and CSs were negative for
the CM marker Troponin I (cTNI). ADHs but not CSs
contained significant numbers of cells for SMCmarker cal-Steponin (CNN; 17.8% ± 3%), or EC marker von Willebrand
factor (vWF; 45% ± 15%) (Figures 1B and 1C; Figure S1A
available online). After 15 days of differentiation, ADH
and CS cells demonstrated similar percentages of CNN+
cells (51% ± 5% versus 42% ± 8%, respectively; p < 0.05),
but ADH demonstrated higher rates of EC differentiation
in comparison with CS (vWF; 49% ± 2% versus 12% ±
7%, respectively; p < 0.05). Compared to ADH cells, differ-
entiated CS-derived cells demonstrated higher percentages
of cTNI+ cells (6.5% ± 3% versus 27% ± 5%, respectively;
p < 0.05). However, these CM-like cells, whereas expressing
low levels of cardiac proteins, did not morphologically
resemble mature myocytes (Figures 1D, 1E, and S1B).
To determine if this incomplete differentiation was
related to our culture conditions or the cells themselves,
we generated CSs from both fetal and adult human hearts
(Figures 2Aa and 2Ai). Differentiated fetal CS-derived cells
exhibited typical CM morphology with organized sarco-
meres that coexpressed the cardiac-specific markers cTNT
and cTNI (Figures 2Ae–2Ah). Although cells from adult
CS actually exhibited higher rates of cells expressing
cTNTand cTNI (27% ± 5% versus 13.3% ± 7%, respectively;
p < 0.05), the absolute expression levels were low, and
sarcomere formationwas rare (Figures 2Am–2Ap; Figure 2B,
right). In contrast, the majority of CMs from fetal CSs
demonstrated spontaneous contractions and calcium tran-
sients (Movies S1 and S2). No differences were observed in
the morphology of fetal or adult CS-derived ECs, but adult
CS-derived cells exhibited lower rates of cells expressing
vWF (12% ± 6% versus 28% ± 4%, respectively; p < 0.05).
Both fetal and adult CS-derived ECs formed typical micro-
tubular capillary networks in Matrigel (Figures 2Ab, 2Ac,
2Aj, and 2Ak; Figure 1B, left). Likewise, SMCdifferentiation
was similar for fetal and adult CS-derived cells (CNN;
64% ± 2% versus 43% ± 16%, respectively; p < 0.05) (Fig-
ures 2Ad and 2Al; Figure 2B, middle).
Human CS Contains a Heterogeneous Population of
Cells
To determine if the difference in differentiation potential
between CS-derived cells from fetal and adult hearts was
due to divergent cell populations, we characterized CS cells
by flow cytometry for the expression of a panel of surface
markers that have been linked to progenitor/stem cells,
including C-KIT, VEGF receptors (FLK1, FLT1, and FLT4),
CD31, CD144, CD34, CD90, CD114, CD184, and CD271
(Baum et al., 1992; Coultas et al., 2005; Nelson et al.,
2008; Shakhova and Sommer, 2010; Shimoji et al., 2010).
We compared the expression of these surface markers on
acutely dissociated mononuclear cells (ADs), HDCs, and
CSs from adult and fetal human hearts (Figure S2A). The
most significant differences were observed in the percent-
age of cells expressing C-KIT, FLT4, CD34, CD90, andm Cell Reports j Vol. 2 j 576–591 j May 6, 2014 j ª2014 The Authors 577
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Figure 1. Cardiovascular Differentiation Potential of Adult Human CS-Derived Cells
(A) Experimental design. Human heart samples were minced, digested, and dissociated to single ADs. ADs were grown in primary adhesion
culture that we call HDCs. After HDCs reached confluence, they were harvested and then cultured in either adhesion cultures (ADHs) or CSs.
After 7 days, ADHs and CSs were induced to differentiate into CMs, SMCs, and ECs.
(B and D) Confocal imaging of ADH and CS cells immunostained with CNN, vWF, and cTNI pre- (B) and post- (D) differentiation. Nuclei were
stained with DAPI (blue). Scale bars, 40 mm.
(C and E) Quantification of the number of cells positive for CNN, vWF, and cTNI from ADH and CS pre- (C) and post- (E) differentiation.
Characterization of HDCs was performed as an additional control of undifferentiated progenitor/precursor cells in the primary culture
(C, green bars). All experiments were performed with a minimum of three independent human heart samples. *p < 0.05.
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Figure 2. Adult Human CS-Derived Cells Differentiate into Immature Cardiomyocytes
(A) Fetal and adult HDCs formed CSs after 1 week in suspension culture (a and i). CS-derived cells formed microtubules after 24–48 hr in
Matrigel angiogenesis assay (b and j). CS-derived cells were plated on coverslips treated with laminin for 15 days to induce cardiovascular
differentiation. Confocal images showed expression of vWF (c and k), CNN (d and l), and cardiac proteins cTNT (green) and cTNI (red)
(e–h and m–p). Sarcomeres were rare in adult CS-derived CM-like cells (m–p). Nuclei were stained with DAPI (blue). Scale bars, 40 mm.
(B) Cardiovascular differentiation (Diff) of HDCs and CS-derived cells pre- and postdifferentiation was quantitated by FACS. All experiments
were performed with a minimum of three independent human heart samples. *p < 0.05.
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Figure 3. Characterization of Fetal and Adult Human HDCs
(A) HDCs were analyzed for a panel of surface markers (x axis) and C-KIT (y axis) by FACS. Percentage of total positive cells for each marker
is shown in the representative dot plot graph.
(B) Percentage of C-KIT cells positive for CD34 and CD90 (hematopoietic markers), CD144 and CD90 (endothelial markers), and NKX2.5
(cardiac progenitor); n = 3.
(C) Costaining for C-KIT (x axis) and NKX2.5 (y axis) in HDCs and CS cells from fetal and adult heart. Percentage of total positive cells for
each marker is shown in the representative dot plot graph.
(D) Comparative table showing the percentage of cells positive for C-KIT, CD31, CD144, CD90, CD34, FLK1, FLT1, FLT4, CD114, CD184, and
CD271 within the NKX2.5 cell population from fetal and adult HDCs and CSs. All experiments were repeated with a minimum of three
independent samples.
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difference between fetal versus adult CSs was the expres-
sion of CD184 (Figure S2).
C-KIT has been the cell surface marker most commonly
used to identify human aCPCs (Bearzi et al., 2007). The
C-KIT+ resident population is very rare in adult compared
to fetal human cells (0.3% ± 0.1% versus 5.5% ± 0.6%,
respectively; p < 0.05). Interestingly, there was a 5- and
2.5-fold increase in C-KIT+ cells in HDCs from adult and580 Stem Cell Reports j Vol. 2 j 576–591 j May 6, 2014 j ª2014 The Authorsfetal hearts, respectively. Because C-KIT is expressed in
aCPCs, hematopoietic, mast cells, endothelial, and certain
fibroblasts (Arsalan et al., 2012; Loffredo et al., 2011; Sand-
stedt et al., 2010), we further phenotyped these C-KIT+ car-
diac cells to delineate their potential origin (Figures 3A
and 3B). The majority of cardiac C-KIT+ cells coexpressed
markers consistent with hematopoietic/EC lineages. Of
the fetal and adult C-KIT+ cells, 68%–85% and 61%–77%,
respectively, were positive for CD34, CD90, CD31, or
Stem Cell Reports
Cardiac Progenitor Cells Are CD90CD144. We also analyzed HDCs and CS cells for the coex-
pression of C-KIT and NKX2.5. Only 10% of C-KIT+ cells
coexpressed NKX2.5 (Figures 3B and 3C). Conversely,
5%–20% of the NKX2.5+ population was C-KIT+ (Fig-
ure 3D). Fetal and adult NKX2.5+ cells were negative for
endothelial surface markers CD31 and CD144, but 50%
coexpressed CD271, a neural crest marker (Figures 3D
and S3). There were dramatic differences in the expression
of CD90, CD34, FLT1, FLT4, and CD184 on NKX2.5+ cells
in fetal compared to adult CS cells (Figure 3D). Thus, C-
KIT identifies a limited subset of NKX2.5+ cells, and
CD271 appears to capture the greatest proportion of the
NKX2.5+ subpopulation in both fetal and adult cells.
Clonal Analysis of Adult CS-Derived Cells Identifies a
Cell with Multilineage Potential
To determine if CS contained cells capable of complete car-
diac differentiation, we dilutionally cloned adult human
CS-derived cells and analyzed their phenotype (Figure 4A).
A total of 16 single CS cells were clonally expanded on
fibronectin-coated plates leading to homogeneous cultures
with elongated, fibroblast-like morphology (Figure S4A).
Seven of the clones stopped proliferating, becoming senes-
cent in the first or second passage and were not analyzed in
further assays (Figure S4B). Six of the long-term prolifera-
tive clones (ID# 2R, 5L, 7L, 5R, 4L, and 8L) were chosen
for further characterization of phenotype, differentiation
potential, and gene expression profile. Flow cytometry
and quantitative PCR (qPCR) demonstrated that all six
clones expressed CD105 (endoglin), chondroitin sulfate
proteoglycan NG2, as well as weak expression for vascular
growth factor receptor Flt4 (Figures 4B and 4C). In contrast,
all clones were negative for endothelial markers (CD31,
CD144, and FLT1), cardiac stem cell markers (FLK1 and
C-KIT), neural crest stem cell marker CD271, and stem
cell mobilization marker CD114. Some clones had weak
expression for CD106 (7L), CD184 (7L and 8L), and
CD34 (5R). CD90 separated the clones into two distinct
subpopulations with differing differentiation potential.
However, there was no obvious difference in morphology
between clones negative for CD90 (2R, 5L, and 7L) or
clones positive for CD90 (5R, 4L, and 8L) (Figure S4A).
To determine if these proliferating clones possess proper-
ties of stem or progenitor cells, we analyzed their ability to
differentiate into the three cell lineages that constitute the
major heart cells. All CD90 clones could differentiate into
cells expressing cardiac-specific genes (a-sarcomeric actinin
[a-actinin], 12% ± 3.7%; a-myosin heavy chain [a-MHC],
2.5% ± 0.7%), with 60% of the a-MHC-expressing cells
demonstrating sarcomeres (1.5% ± 1% of total cells; Figures
4D–4F and S4C). CD90 clones could also differentiate into
SMCs (CNN, 30% ± 7.5%) and ECs (vWF, 5% ± 4%). In
contrast, although some CD90+ clones could express lowStelevels of cardiac-specific proteins (a-actinin, 1% ± 0.5%,
and a-MHC, 0.75% ± 0.1% of total cells), they did not
form mature CMs with complete sarcomeres (Figures 4D–
4F). CD90+ clones were at least as efficient as CD90 clones
in differentiating into SMCs (CNN, 35% ± 14%) and ECs
(vWF, 33% ± 14%). These data suggest that the CD90 sub-
population contains a cell with cardiogenic potential.
Adult Human CS-Derived CD90 and CD90+ Clones
Display Distinct Transcriptional Profiles
To characterize gene expression in CD90 versus CD90+
clones, we assayed the expression of aCPC candidate genes.
ISL-1was 10.5-fold elevated in CD90 versus CD90+ clones
(Figure 5A; p < 0.05). In contrast, expression of fibroblast/
myofibroblast gene Periostin was 3.9-fold higher, respec-
tively, in CD90+ versus CD90 clones (Figure 5A; p <
0.05), suggesting a fundamentally different phenotype be-
tween the two type of clones. To examine genome-wide
expression patterns, we performed next-generation RNA
sequencing (RNA-seq). The gene expression profiles of
22,449 genes were examined after removal of duplicate
genes following transcript aligning. The low number of
CD90 transcripts in the negative versus positive clones
confirmed phenotypes of samples (Figure S5). Hierarchical
clustering analysis further revealed the molecular differ-
ence between the CD90 and CD90+ clones (Figure 5B). A
total of 272 genes were differentially expressed in CD90
versus CD90+ clones, of which 133 genes were upregulated
and 139 downregulated in CD90 as compared to CD90+
(Table S1). The fold change ofmajor genes differentially up-
regulated (red) and downregulated (green) in CD90 versus
CD90+ clones is shown in Figure 5C.
To better characterize the molecular basis of the cellular
phenotypes and differentiation potential of CD90 and
CD90+ clones, we used Gene Ontology (GO) enrichment
analysis and canonical pathway analysis to functionally
annotate and predict the biological roles of these genes
(Figure 5D; Tables S2 and S3). Biological processes that
were preferentially represented in the CD90 clones were
those associated with embryonic morphogenesis, muscle
cell development, proliferation, and telomere mainte-
nance consistent with progenitor-like behavior (Table S2).
The most enriched pathway in CD90 clones was the
Oct4 and mammalian embryonic stem cell pluripotency
pathway (CCNF, PHC1, NR2F6, and ASH2L) (Campbell
et al., 2007). In contrast, upregulated genes inCD90+ clones
point to networks and pathways of filament-forming cyto-
skeletal and motility and migration of activated fibroblasts
(PAK4, SEPT1, MMP2, and FAP) (Abo et al., 1998; Stawowy
et al., 2004; Howard et al., 2012). Transcriptome profiling
suggests that humanCD90CS-derived clones are enriched
in expression of genes related to stemness, whereas CD90+
clones were enriched with fibroblast-associated genes.m Cell Reports j Vol. 2 j 576–591 j May 6, 2014 j ª2014 The Authors 581
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Figure 4. CD90 CS-Derived Clones Are Multipotent, Giving Rise to Mature CMs
(A) Schematic diagram outlining the strategy for cloning and analysis of CS-derived cells.
(B) Characterization for cell surface markers on long-term proliferative CS-derived clones by FACS (n = 6 clones).
(C) Quantitative RT-PCR analysis of CD90 and CD105 expression in long-term proliferative CS-derived clones (n = 6). *p < 0.05.
(D) CS-derived clones were differentiated and immunostained for a-actinin (a-SA) and CNN or a-MHC, and vWF and imaged by confocal
microscopy. Nuclei were stained with DAPI (blue). Scale bars, 40 mm and 5 mm (inset).
(E) FACS quantification of a-MHC, a-SA, CNN, and vWF in CD90 and CD90+ clones (n = 6). *p < 0.05.
(F) Percentage of cardiomyocytes with mature sarcomere formation from CD90 (orange bars) and CD90+ (green bars) clones (n = 6).
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Cardiac Progenitor Cells Are CD90Adult CD90 CS-Derived Cells Have Limited Capacity
to Differentiate into More Mature CMs
To determine how specific the lack of CD90 expressionmay
be for the identification of aCPCs in CSs, we isolated and582 Stem Cell Reports j Vol. 2 j 576–591 j May 6, 2014 j ª2014 The Authorscloned directly by fluorescence-activated cell sorting
(FACS) CD90 and CD90+ adult human CS-derived cells
(Figure S6A). Purity of individual clones was confirmed,
and 21 CD90 clones and 24 CD90+ clones were recovered.
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Figure 5. Transcriptome Profile of CS-Derived Clones
(A) Quantitative real-time PCR analysis for ISL-1, NKX2.5, Periostin, and SMA in CD90 and CD90+ CS-derived clones.
(B) Hierarchical clustering analysis of the four CS-derived clones. Differential gene expression was determined using the mean for each
sample of CD90 clones versus CD90+ clones. Hierarchical clustering analysis was performed using Partek Genomic Suite software.
(C) Differential expression of genes upregulated (red) and downregulated (green). Blue line represents p value of <0.05.
(D) Pathway analysis using ingenuity pathway analysis (IPA). Significant enrichment of canonical pathways in CD90 samples versus
CD90+ samples (gray bars) is shown. Blue line represents ratio.
n = 6; *p < 0.05.
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Cardiac Progenitor Cells Are CD90Of CD90+ clones, 79.1% stopped proliferating within
30 days in culture in contrast to only the 47.6% of
CD90 clones (Figures S6B and S6C). Long-term prolifera-
tive CD90 and CD90+ clones grew with a doubling time
between 36 and 72 hr (Figure S6C, right). A total of 21
CD90 and 11 CD90+ clones were chosen for further char-
acterization of differentiation potential and gene expres-
sion profile before and after differentiation (scheme in
Figure 6A). Of CD90 clones, 28.5% (6 of 21 total CD90
clones: #5, #10, #14, #16, #17, and #19) were tripotent
for the 3 cell lineages (Figures 6Ba–6Bc, 6C, and 6D),
47.6% of CD90 clones were bipotent for myogenic
lineages (CM and SMC), and the remaining 23.8% of
CD90 clones were unipotent for SMCs (Figures 6C and
6D). Of 21 CD90 clones analyzed, 16 were cardiomyo-
genic, expressing a-actinin (Figures 6C and S6D), whereas
only 1 CD90+ clone of 11 clones was tripotent (clone
number #36), with less than 5% a-actinin-positive cells,
55% of CD90+ clones differentiated into vascular lineages
(SMC and EC), and 36% of CD90+ clones were unipotent
(3 clones for SMCs [#22, #35, and #45] and 1 clone for
ECs [#41]) (Figures 6Bf–6Bh and 6C). After 90 days in cul-
ture, some CD90 clones went on to form more mature
CMs with complete sarcomeres but at a low rate (<1%) (Fig-
ures 6Bd and 6Be). Sarcomere formation was never seen
with CD90+ clones.
We determined the expression of candidate genes in
CD90 versus CD90+ clones. ISL-1 mRNA was elevated 4-
fold in undifferentiated CD90 clones, whereas Periostin
was 3-fold elevated in CD90+ clones. Late CM gene cTNT
was elevated 2-fold in CD90 clones after differentiation,
but no increase was observed in CD90+ clones (Figure 6G).
We also analyzed expression of integrins associated with
maturation of cardiomyocytes (Maitra et al., 2000). Integ-
rin a7 (INTA7) was elevated 6-fold in differentiated
CD90 clones versus CD90+ clones (Figure 6H). Integrin
a5 (INTA5) was expressed at similar levels in both clones
(Figure S6E). Skeletal muscle differentiation could not
explain our results because myogenin expression was not
observed before or after differentiation in CD90 and
CD90+ clones (Figure S6F). Expression of CD90 did not
change with differentiation (Figure 6I).
To confirm that the CD90 population contains
an aCPC, we made CS directly from sorted CD90 and
CD90+ fractions obtained from fetal HDCs (Figure 7A).
CS-derived cells from theCD90 fractionweremore cardio-
genic and more likely to undergo complete CM differenti-(C) Quantification of a-actinin, CNN, and vWF in CD90 (16 clones) a
(D) Differentiation potential of CD90 and CD90+ CS-derived clones: tr
or unipotent (SMC or EC lineages).
(E–I) Quantitative real-time PCR analysis for ISL-1, cTNT, INTA7, Per
*p < 0.05. undiff., undifferentiated.
Steation (Figures 7B–7D): cTNI, 10% ± 8% versus 2.6% ±
1.5% and 2.3% ± 1.5% for CD90 versus CD90+ and un-
sorted cells, respectively (p < 0.05); cTNT, 25% ± 11%versus
6.9% ± 3.7% and 11% ± 4% for CD90 versus CD90+ and
unsorted cells, respectively (p < 0.05).DISCUSSION
Tissue-specific stemor progenitor cells are notoriously diffi-
cult to expand and propagate in vitro in an undifferenti-
ated state. Various culture systems have been developed
in an attempt to maintain stemness in these cells,
including a 3D culture system based on sphere formation.
We utilized CS generated from fetal and adult hearts to
attempt to identify an aCPC that has the capacity to differ-
entiate into CMs, SMCs, and ECs. Fetal and adult CS-
derived cells differentiated into vascular lineages like
SMCs and ECs with similar efficiencies. However, whereas
functional CMs were easily derived from fetal CS, the
majority of adult CS-derived CMs did not form sarcomeres
or exhibit calcium cycling despite expression of relevant
cardiac-specific genes. We cloned cells from adult CS
and demonstrated two distinct populations of cells
with differing cardiovascular differentiation potential.
The first cell type has properties consistent with a CPC
(CD90/ISL1hi/Periostinlo), including potential to differen-
tiate into more mature CMs, although the percentage of
mature CMs obtained was very low (<1%). This was not
simply a technical issue related to our differentiation
conditions because multiple published protocols were
tested (Figures S7A–S7C). Likewise, the fact that cells iso-
lated from CS, which were derived directly from CD90
cells, demonstrated cardiogenic differentiation suggests
that CM dedifferentiation cannot explain these results.
Although these results support the conclusion that CSs
contain an aCPC with cardiogenic potential, it is unlikely
that this differentiation could explain any therapeutic ef-
fect given its rarity. Furthermore, the explanation for why
formation of mature CMs occurs at such a low efficiency
even from clones with cardiogenic potential is unclear.
Whether it is related to limitations of the artificial in vitro
differentiation conditions or represents a block to differen-
tiation in these cells will require further studies. Regardless,
generation of sufficient aCPCs in vitro to regenerate
injured hearts will require the discovery of novel tech-
niques to expand and differentiate these cells.nd CD90+ (11 clones) CS-derived clones.
ipotent (CM/SMC/EC lineages), bipotent (CM/SM; SMC/EC lineages),
iostin, and CD90 in CD90 and CD90+ CS-derived clones (n = 26).
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Cardiac Progenitor Cells Are CD90The second cell type appeared to be a cardiac
mesenchymal/fibroblast-like cell that was CD90+/ISL1low/
Periostinhi and capable of forming SMCs and ECs and
partial differentiation into cardiac protein-expressing
cells without sarcomere formation. CD90+ clones demon-
strated higher expression of fibroblast-associated genes
including Periostin compared to CD90 clones. Periostin
is the marker most commonly used to identify cardiac
fibroblasts (Norris et al., 2008; Snider et al., 2009). Multi-
potent human fibroblasts have been described in other
tissues such as dermis (Chen et al., 2007), but in this study
we describe a multipotent cardiac fibroblast (CD90+/
Periostin+) in the human heart. These data are consistent
with multiple studies that have described ‘‘cardiac progen-
itor/precursor cells’’ from multiple tissues such as heart
(Simpson et al., 2012), bone marrow (Deb et al., 2003;
Toma et al., 2002), adipose tissue (Fraser et al., 2006;
Armin˜a´n et al., 2009), or dental pulp (Armin˜a´n et al.,
2009) that undergo incomplete cardiac differentiation.
This has also been observed in other systems because hu-
man embryonic stem cell-derived mesenchymal progeni-
tors express cardiac markers but do not form contractile
cardiomyocytes (Raynaud et al., 2013; Ramkisoensing
et al., 2011). Given the presence of cells in the adult heart
with incomplete cardiogenic potential, which are not true
CPCs, the ability to form sarcomeres and display calcium
cycling should be an essential component for defining
an ‘‘authentic’’ cardiac progenitor cell.
Human CS-derived CD90 clones are multipotent and
could form mature CMs. These cells displayed a distinct
cell surface marker phenotype and a unique stem cell-like
transcriptome. Clones negative for CD90 also expressed
cardiac progenitor transcription factors NKX2.5 and ISL-1
(Bu et al., 2009; Moretti et al., 2006; Wu et al., 2006). These
results are in concordance with earlier studies suggesting
that a SCA1+ cardiogenic subpopulation in CS-derived
cells is enriched for Isl1 expression (Ye et al., 2012). In fact,
genome-wide expression analysis using next-generation
sequencing revealed differential gene expression in CD90
clones involved in pluripotency and stemness (Pardo et al.,
2010). Interestingly, we observed a dramatic increase in
INTA7 expression in CD90 clones with differentiation.
a7-integrin forms a heterodimer with b1-integrin in termi-
nal-differentiated cardiomyocytes in heart development
and is progressively increased in adult stage (Maitra et al.,
2000). The importance of the integrin receptor, a7b1, in
thecorrect assemblyofcytoskeletonproteins to formmature
and functional CMs is an important unresolved issue.(E) Working model of CS-derived cell lineages from adult human hea
cardiomyogenic differentiation; CD90/ISL-1hi/Periostinlo with limited
with ECs and SMCs and a cardiac mesenchymal/fibroblast cell that wa
CM-like cells without sarcomere formation (CM-like immature), ECs, a
SteCD90 and CD90+ clones share expression of some
mesenchymal genes such as NG2, CNN, and CD105.
Whether this indicates two cell types representing different
developmental stages of a similar mesenchymal precursor
will need to be determined. The exact identity of the CS-
derived CD90 aCPC remains to be determined. Although
C-KIT has been reported to identify resident cardiac stem
cells (Bearzi et al., 2007; Beltrami et al., 2003), it was not ex-
pressed on most NKX2.5+ cells in CSs nor was it expressed
on the CD90 cardiogenic clones we analyzed. Conversely,
themajority of C-KIT+ cells in fetal and adult hearts did not
expressNKX2.5. Our results suggest that themajority of the
C-KIT population inhumanheart expressesmarkers consis-
tent with a hematopoietic/endothelial lineage (C-KIT+/
CD90+/CD34+; C-KIT+/CD90+/CD144+). C-KIT+/CD90
CS-derived cells were cardiogenic, but they did not demon-
strate sarcomere formation (Figures S7D and S7E). Consis-
tent with our results, it has been reported that unselected
human CS-derived cells are functionally superior to C-
KIT+/CD90 or CD90+ purified CS-derived cells (K. Cheng
et al., 2012, Circulation, abstract; R.R. Smith et al., 2008,
Circulation, abstract). Whether C-KIT+/NKX2.5+ cells
represent the endogenous aCPC and the CD90/C-KIT/
NKX2.5low we cloned are related or this CD90/C-KIT/
NKX2.5low clone is a unique CPC is impossible for us to
determine because identification of NKX2.5+ cells required
fixing and permeabilizing the cells. The neural crest marker
CD271 was able to identify the largest proportion of the
NKX2.5 population in the heart but was not expressed on
our CD90 clones. Resolution of this issue will require iden-
tifying additional cell surface markers so that endogenous,
live cells can be isolated directly. Interestingly, dramatic
changes in the expression of surface markers including
C-KIT were observed in cell culture. The surface marker
changing most dramatically was CD90, decreasing from
80% to 10% in fetal and 40% to 10% in adult freshly disso-
ciated cells to CSs, respectively (Figure S2). An epithelial-to-
mesenchymal transition mechanism has been reported to
occur within CS that is associated with downregulation of
CD90 expression (Forte et al., 2012). Thus, whether the
CS-derived CD90 aCPC clones we isolated exist endoge-
nously in humanhearts or are a byproduct of theCS culture
system remains to be determined.
Taken together, these findings suggest a working model
to define CS-derived cell lineages with cardiovascular
differentiation potential from the adult human heart (Fig-
ure 7E). In this model, CD90 expression segregates adult
human CS-derived cells with differing cardiomyogenicrt. CD90 differentiates adult human CS-derived cells with differing
potential to differentiate into CMs with sarcomere formation along
s CD90+/ISL-1low/Periostinhi capable of partial differentiation into
nd SMCs.
m Cell Reports j Vol. 2 j 576–591 j May 6, 2014 j ª2014 The Authors 587
Stem Cell Reports
Cardiac Progenitor Cells Are CD90differentiation. Our study suggests the presence of a ‘‘true’’
adult CPC versus a mesenchymal/myofibroblast cell that
can express cardiac proteins but not differentiate into a
true CM.EXPERIMENTAL PROCEDURES
Derivation of Primary Cardiac Cell Culture from
Human Heart Samples
A total of 32 human biopsies were obtained from 32 donors
(16 fetal and 16 adult). Fetal heart tissue was harvested under the
supervision of the UCLA institutional review board, and adult hu-
man heart tissue was harvested from discarded pathological speci-
mens at the time of heart transplantation under the supervision of
the UCLA institutional review board or at the time of left ventric-
ular assist device (LVAD) placement under the supervision of the
UW institutional review board (Table S4). Biopsies were stored in
Ca2+/Mg++-free Dulbecco’s PBS (DPBS; Cellgro) supplemented
with 2% penicillin/streptomycin (P/S) and processed at a
maximum of 4 hr postsurgery. Further details of heart dissociation
and primary culture of HDCs are described in the Supplemental
Experimental Procedures.Generation of CS
Confluent HDCs were washed with DPBS, trypsinized with a 0.1%
trypsin solution (Sigma-Aldrich) for 4 min at 37C, neutralized
with serum, centrifuged at 1,200 rpm for 5 min, and finally resus-
pended in CS growth media (CGM): 70% DMEM:F12 1:1 (Invitro-
gen)/30% IMDM (Lonza), 0.001% 2-mercaptoethanol (Sigma-
Aldrich), 40 nM thrombin (Sigma-Aldrich), 40 nM cardiotrophin
(PeproTech), 2% B27 (Gibco), 10 ng/ml epidermal growth factor
(EGF; R&D Systems), 20 ng/ml basic fibroblast growth factor
(bFGF; PeproTech), and antibiotics and L-glutamine into 0.8%
methylcellulose (R&D Systems). Cells were seeded at a density of
25,000 cells/cm2 in an untreated 60 mm culture dish (BD Falcon).
Every 48 hr, EGF and bFGF were added to the culture medium. For
ADH cultures, the pellet was resuspended and cultured at a density
of 5,000 cells/cm2 in T-75 culture flasks (BD Falcon) precoatedwith
fibronectin (20 mg/ml) in growth media (Figure 1A).Cardiovascular Differentiation In Vitro
Primary CS (5–10 U) or ADHs (10,000 cells/cm2) were seeded on
12-mm-diameter laminin-coated (Sigma-Aldrich) coverslips (Men-
zel-Gla¨ser, http://www.menzel.de). Four distinct differentiation
media were used for cardiovascular differentiation: basal medium,
cardiomyogenic medium, smooth-muscle medium, and endothelial
medium. For EC tube formation assay, we followed the BD protocol
(BD Matrigel matrix catalog number 354234). All differentiation
experiments were performed for 2–3 weeks, replacing differentia-
tionmedia every 3 days. Further details are described in the Supple-
mental Experimental Procedures.Immunofluorescence in Cover Slides and Cytospin
We performed immunofluorescence as described in the Supple-
mental Experimental Procedures. All slides were analyzed by588 Stem Cell Reports j Vol. 2 j 576–591 j May 6, 2014 j ª2014 The Authorsconfocal microscopy (LEIKA SP2 1P-FCS Confocal and NIKON
A1R Confocal).Calcium Fluorescence Imaging
Cell cultureswere incubatedwith the fluorescent calcium indicator
dye Fluo-4 AM (10 mM; Invitrogen) and nonionic surfactant Plur-
onic F-127 (0.02%; Invitrogen) in cardiomyogenic medium. Spon-
taneous calcium fluorescence activity was imaged and recorded.
Further details are described in the Supplemental Experimental
Procedures.Flow Cytometry
We performed FACS analysis as described in the Supplemental
Experimental Procedures. Data were acquired in a FACS LSRII
flow cytometer (BD Biosciences). Gating strategy is described in
Figure S1. FACSDIVA software (BD Biosciences) was used for acqui-
sition of data. For later analyses, we used FlowJo software (version
7.6.5).Cell Sorting
We performed FACS as described in the Supplemental Experi-
mental Procedures. Sorting experiments were done on a
FACSAria III cell sorter (BD Biosciences), at low sheath pressure
and by using a nozzle of 80 mm in diameter.Clonal Assay
CS-derived cells were trypsinized and centrifuged. Pellet was resus-
pended in growthmedium, and cell number was determined using
a hemocytometer. We performed clonal assay as described in the
Supplemental Experimental Procedures. All the cells from individ-
ual clones were analyzed by FACS flow cytometer, RNA isolation
for qPCR and RNA-seq, and for differentiation potential.RNA Isolation and Quantitative Real-Time-PCR
We performed RNA isolation and quantitative real-time PCR as
described in the Supplemental Experimental Procedures.RNA-Seq
We performed whole-genome transcriptomic analysis as described
in the Supplemental Experimental Procedures.Statistical Analyses
Results are presented as the mean ± SEM of a number (n) of inde-
pendent experiments. p values were calculated using GraphPad
software. Differences in multiple groups were evaluated using
ANOVA. Correlation was deemed significant at the p < 0.05 level
(two tailed).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, seven figures, four tables, and two movies and can be
found with this article online at http://dx.doi.org/10.1016/j.
stemcr.2014.03.003.
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